Article Details

Allarity Therapeutics' oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral ...

Retrieved on: 2021-08-05 10:52:30

Tags for this article:

Click the tags to see associated articles and topics

Allarity Therapeutics' oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral .... View article details on hiswai:

Excerpt

In combination with remdesivir, researchers observed a 95% reduction in virus. This reduction was measured as an average of plaque counts in three ...

Article found on: finance.yahoo.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up